Total Payments
$135,068
2024 Payments
$1,754
Companies
37
Transactions
279
Medicare Patients
2,719
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$106,438 (78.8%)
Consulting$16,130 (11.9%)
Travel$6,374 (4.7%)
Food & Beverage$5,878 (4.4%)
Education$248.84 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $106,438 | 46 | 78.8% |
| Consulting Fee | $16,130 | 11 | 11.9% |
| Travel and Lodging | $6,374 | 14 | 4.7% |
| Food and Beverage | $5,878 | 203 | 4.4% |
| Education | $248.84 | 5 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $47,632 | 56 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $33,398 | 21 | $0 (2023) |
| Celgene Corporation | $24,023 | 64 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $23,739 | 14 | $0 (2017) |
| Janssen Biotech, Inc. | $4,256 | 20 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $343.80 | 15 | $0 (2023) |
| Astellas Pharma US Inc | $206.56 | 7 | $0 (2024) |
| ABBVIE INC. | $166.34 | 8 | $0 (2024) |
| Genentech USA, Inc. | $151.67 | 8 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $141.42 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,754 | 18 | Janssen Biotech, Inc. ($1,413) |
| 2023 | $687.93 | 30 | Celgene Corporation ($197.27) |
| 2022 | $2,090 | 18 | Janssen Biotech, Inc. ($1,819) |
| 2021 | $66.53 | 3 | Pharmacyclics LLC, An AbbVie Company ($53.08) |
| 2020 | $11,020 | 15 | Amgen Inc. ($7,596) |
| 2019 | $38,884 | 70 | Takeda Pharmaceuticals U.S.A., Inc. ($17,541) |
| 2018 | $26,166 | 59 | Takeda Pharmaceuticals U.S.A., Inc. ($12,457) |
| 2017 | $54,399 | 66 | Millennium Pharmaceuticals, Inc. ($23,739) |
All Payment Transactions
279 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: BioOncology | ||||||
| 12/04/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/25/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $31.80 | General |
| Category: Hematology | ||||||
| 11/12/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $21.30 | General |
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $62.99 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.84 | General |
| Category: Hematology | ||||||
| 09/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.21 | General |
| Category: Hematology | ||||||
| 03/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.80 | General |
| Category: Hematology | ||||||
| 12/13/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: Oncology | ||||||
| 11/19/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.32 | General |
| Category: Hematology | ||||||
| 11/01/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $27.75 | General |
| Category: Hematology | ||||||
| 10/30/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.75 | General |
| Category: Hematology | ||||||
| 10/10/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 606 | 11,413 | $1.7M | $420,524 |
| 2022 | 22 | 658 | 10,211 | $1.4M | $391,419 |
| 2021 | 17 | 506 | 6,515 | $882,737 | $255,764 |
| 2020 | 33 | 949 | 26,141 | $1.7M | $514,961 |
Total Patients
2,719
Total Services
54,280
Medicare Billing
$1.6M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 24 | 7,740 | $1.2M | $293,412 | 23.9% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 24 | 1,760 | $236,930 | $58,795 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 230 | $133,733 | $31,200 | 23.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 77 | $33,473 | $8,341 | 24.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 48 | 107 | $26,682 | $6,272 | 23.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 63 | 105 | $23,166 | $5,471 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $19,469 | $4,444 | 22.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 81 | 411 | $10,025 | $3,428 | 34.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 29 | $11,797 | $2,738 | 23.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 48 | 144 | $10,054 | $2,414 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 18 | $7,129 | $1,511 | 21.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 32 | $2,820 | $740.75 | 26.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 19 | $1,834 | $427.85 | 23.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 28 | $1,456 | $355.10 | 24.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 14 | $1,585 | $349.44 | 22.0% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2023 | 23 | 430 | $1,343 | $287.78 | 21.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 25 | $1,190 | $287.25 | 24.1% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 14 | 17 | $148.00 | $34.44 | 23.3% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 15 | 200 | $70.80 | $15.11 | 21.3% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2022 | 23 | 7,020 | $977,400 | $256,266 | 26.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 19 | 1,500 | $155,820 | $46,049 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 79 | 188 | $71,228 | $25,799 | 36.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 65 | 311 | $83,079 | $25,358 | 30.5% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 30 | 43 | $19,888 | $6,647 | 33.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 35 | 56 | $20,622 | $6,443 | 31.2% |
About Dr. Tara Gregory, M.D
Dr. Tara Gregory, M.D is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1407973993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tara Gregory, M.D has received a total of $135,068 in payments from pharmaceutical and medical device companies, with $1,754 received in 2024. These payments were reported across 279 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($106,438).
As a Medicare-enrolled provider, Gregory has provided services to 2,719 Medicare beneficiaries, totaling 54,280 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Denver, CO
- Active Since 03/22/2007
- Last Updated 10/21/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1407973993
Products in Payments
- NINLARO (Drug) $56,997
- Kyprolis (Biological) $39,896
- Revlimid (Drug) $16,106
- Kyprolis (Drug) $4,028
- TALVEY (Biological) $1,350
- DARZALEX (Biological) $1,076
- CC-92480 (Drug) $335.49
- Pomalyst (Drug) $217.78
- REBLOZYL (Biological) $204.17
- IMBRUVICA (Drug) $197.00
- Imbruvica (Drug) $194.90
- Blincyto (Biological) $116.45
- VYXEOS (Drug) $94.14
- VELCADE (Drug) $80.24
- Cresemba (Drug) $78.74
- GAZYVA (Biological) $78.48
- CARVYKTI (Biological) $76.24
- EPKINLY (Drug) $73.34
- JAKAFI (Drug) $65.70
- VONJO (Drug) $47.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100